By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Parkinson Plus Stages: The Process from Onset to Advanced Phases
Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB), the conditions often called Parkinson Plus, are described by milestones, not numbered stages. The pace varies between conditions and people, so this page is a framework, not a timetable.
Are there numbered stages in Parkinson Plus?
No. The guidance and reviews cited here define no stage scale for MSA, PSP, CBD or DLB. If you see a five-stage description of Parkinson Plus elsewhere, ask what it is based on.
What they do describe is a wide range of speed. The NHS says DLB usually gets worse slowly over several years, while CBD brings gradually worsening problems with movement, speech, memory and swallowing. A 2026 review by Kukkle and colleagues reports different survival periods for different forms of PSP. For what the group includes, see Overview of Parkinson Plus disease.
Which milestones are described?
Each condition tends to start in a different place and add problems over time. Not everyone goes through every milestone, and the order can change.
| Condition | Where it often starts | What can be added later |
|---|---|---|
| MSA | Problems with automatic body functions (autonomic problems), such as dizziness on standing or bladder trouble, can come before movement problems, in 20% to 75% of cases (Cleveland Clinic) | Slowness and stiffness, or loss of balance and coordination (ataxia), become clearer. Some people need a wheelchair, later a bed (Cleveland Clinic) |
| PSP | Poor balance with early falls, and trouble looking up or down (Brain Foundation) | Swallowing difficulty. The Brain Foundation names pneumonia as the most common cause of death |
| CBD | Difficulty controlling one limb, often on one side first (NHS) | Speech, memory and swallowing problems increase. Swallowing problems can cause pneumonia (NHS) |
| DLB | Visual hallucinations, fluctuating confusion or sleepiness, movement symptoms (NHS) | Usually worsens slowly over several years; medicines may control some symptoms for a time (NHS) |
Some of these entries are hard to read. They describe what can happen across groups, not what will happen to one person. Symptoms in each condition are set out on What is Parkinson Plus, early symptoms and daily life.
What survival figures have been reported?
The periods differ because the sources count from different starting points: the first symptoms, diagnosis, or, in one study, the day people joined it. All are group averages or medians, not forecasts for one person. You may prefer to go through them with the doctor who knows the person's situation.
| Condition | Reported period | Counted from | Source |
|---|---|---|---|
| MSA | Average 6 to 10 years, up to 15 in milder cases | Not stated | Cleveland Clinic |
| MSA | Median 9.8 years (likely range 8.8 to 10.7) | Start of symptoms | Low and colleagues |
| MSA | Median 1.8 years (likely range 0.9 to 2.7) | Joining the study | Low and colleagues |
| PSP, Richardson syndrome | 5 to 7 years | Not stated in the abstract | Kukkle and colleagues |
| PSP, PSP-parkinsonism | 8 to 12 years | Not stated in the abstract | Kukkle and colleagues |
| PSP | 5 to 9 years | After diagnosis | Brain Foundation |
| CBD | About 6 to 8 years, an average with wide variation | Start of symptoms | NHS |
| DLB | About 5 to 7 years, highly variable | After diagnosis | NHS |
The two MSA figures from Low and colleagues show why the starting point matters. They followed 175 people with probable MSA at 12 US centres for 5 years. The authors link the gap between 9.8 and 1.8 years to late diagnosis and describe probable MSA as a late-stage disease with short survival at diagnosis.
For PSP, the figures do not confirm each other, but they do not clearly conflict either. Kukkle and colleagues give figures for only two of the four recognised forms. The Brain Foundation's patient page counts from diagnosis and adds that with good care most people live into their 70s or beyond. That is its statement, not a study result.
Only MSA has figures for loss of independence here. Cleveland Clinic says about 60% of people need a wheelchair roughly five years after symptoms begin, and at least half are bedridden within 6 to 8 years. These percentages should not be applied to the other conditions.
Does anything predict a faster or slower course?
Some features are linked to shorter survival in MSA, but they describe groups and cannot predict one person's course.
- Severe autonomic symptoms that begin before movement symptoms, older age at diagnosis and frequent falls (Cleveland Clinic)
- Severe autonomic failure at diagnosis: median survival of 8.0 years, compared with 10.3 years without it (Low and colleagues)
Low and colleagues judged the parkinsonian (MSA-P) and cerebellar (MSA-C) types to have similar natural histories. For PSP, Kukkle and colleagues give shorter figures for Richardson syndrome than for PSP-parkinsonism. No comparable features are given for CBD or DLB.
How does care change as symptoms are added?
Care is built around the problem that appears, not around a stage number. Examples are:
- Balance and daily tasks: physiotherapy and occupational therapy (Brain Foundation, NHS)
- Speech and swallowing: speech therapy, with dietetics for nutrition in PSP (Brain Foundation)
- Eye problems in PSP: botulinum toxin, an injected muscle-relaxing medicine, or artificial tears (Brain Foundation)
- Stiffness, spasms, sleep, mood, pain or memory in CBD: medicines chosen for the symptom (NHS)
- Hallucinations, confusion, drowsiness, movement and sleep problems in DLB: medicines, with cognitive stimulation (NHS)
- Palliative care, which focuses on comfort and support, as part of the CBD care team (NHS)
Levodopa, the main Parkinson's medicine, helps less in these conditions: Cleveland Clinic says it works less well in MSA, and the Brain Foundation says its benefit in PSP may fade within 1 to 2 years. These sources describe no treatment that stops MSA, PSP or CBD from progressing, and the NHS says none is proven to slow DLB, which is why care targets the symptoms. Transcranial magnetic stimulation (TMS) and deep brain stimulation have not been shown to change the course; the research is described on Parkinson Plus and TMS.
You can ask the care team:
- When will swallowing be assessed, and what options exist if it worsens?
- How will the risk of falls be handled?
- How will the team judge whether a medicine is still helping?
- When should palliative care join the team?
How such a team can be put together is covered on Parkinson Plus treatment, the care process, and a guide for families facing a new diagnosis is on Parkinson Plus syndrome, a map for the journey.
Which changes need attention without waiting?
Fainting, a fall that causes injury, coughing or choking when swallowing, and a cough with fever or breathlessness should be checked without waiting for the next appointment. Call emergency services for choking that does not clear, severe breathlessness or a serious injury from a fall. The NHS says swallowing problems in CBD can cause pneumonia, which can be life-threatening, and lists faints and falls among DLB symptoms. Cleveland Clinic names pneumonia and a urinary infection that spreads to the blood (sepsis) among the common causes of death in MSA.
Sources
- Cleveland Clinic: Multiple System Atrophy (MSA)
- Low and colleagues, Natural history of multiple system atrophy in the USA (2015)
- Kukkle and colleagues, Progressive Supranuclear Palsy: A Global Review (2026)
- Brain Foundation: Progressive Supranuclear Palsy (PSP)
- NHS: Corticobasal degeneration
- NHS: Dementia with Lewy bodies
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson Plus